News - News - MicroPort® CardioFlow

News

Always Share with You
Every Bit of Our Progress

News

2023.12.29

MicroPort^® CardioFlow Completed the First Overseas Clinical Application of TMVR System Under Compassionate Use, with Excellent 30-Day Follow-Up Results

Read More
2023.12.29

MicroPort^® CardioFlow Completed the First Implantation of VitaFlow Liberty^® in Russia

Read More
2023.12.15

MicroPort^® CardioFlow Receives Approval for Alwide^® Plus in Saudi Arabia

Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.

Read More
2023.11.25

MicroPort^® CardioFlow's VitaFlow^® has Excellent Long-Term Clinical Outcomes, 7-Year Follow-Up Data Presented at PCR London Valves

London, UK - November 19th - November 21st, 2023, evidence-based data from the VitaFlow® Transcatheter Aortic Valve (VitaFlow®), developed by MicroPort® CardioFlow (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK), were revealed on PCR London Valves, a leading global event on structural heart diseases. The data showed that the long-term and excellent clinical outcomes of VitaFlow® have reached the international mainstream level, and this is also the first time for the domestically-developed transcatheter aortic valve system to publish 7-year long-term follow-up data in the international authoritative academic arena in the field of interventional treatment of heart valve disease.

Read More
2023.11.03

MicroPort^® CardioFlow Receives Approval for VitaFlow Liberty^® and Alwide^® Plus in Indonesia

Shanghai, China, MicroPort® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort® CardioFlow, stock code: 02160.HK) has recently received marketing approval for its VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System (hereinafter referred to as "VitaFlow Liberty®" ) and Alwide® Plus balloon catheter (hereinafter referred to as "Alwide® Plus") from the Indonesian Ministry of Health (MOH).

Read More

<5 6 7 8 9 10 11 12 13 14 15 >

Privacy settings

This website may store cookies on your browser. Cookies are mostly used to make the website work asyou expect it to. No cookie will directly identify you, but it can give you a more personalized browsingexperience.

CardioFlow Medtech respects your privacy rights, so you can block some types of cookies. Technically non-essentialcookies and tracking mechanisms, that enable us to provide you with customized offers (marketingcookies), are only used if you have given prior consent to such use.

Strictly necessary cookies

Consent to marketing cookies

By clicking "Save", only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings. For more information, please see our Cookie Policy.

TOP

互联网药品信息服务资格证书编号：（沪）-非经营性 - 2024 - 0135

“MicroPort CardioFlow”及“ are registered trademarks of MicroPort CardioFlow Medtech Corporation.